AshleighMcClendonDO

PubMed

• Targeting cell cycle and hormone receptor pathways in cancer.
  Comstock, C. E.,Augello, M. A.,Goodwin, J. F.,de Leeuw, R.,Schiewer, M. J.,Ostrander, W. F.,Burkhart, R. A.,McClendon, A. K.,McCue, P. A.,Trabulsi, E. J.,Lallas, C. D....> ;Oncogene. 2013 May 27
• CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.
  McClendon, A. K.,Dean, J. L.,Rivadeneira, D. B.,Yu, J. E.,Reed, C. A.,Gao, E.,Farber, J. L.,Force, T.,Koch, W. J.,Knudsen, E. S.> ;Cell Cycle. 2012 Jul 04
• RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
  Knudsen, E. S.,McClendon, A. K.,Franco, J.,Ertel, A.,Fortina, P.,Witkiewicz, A. K.> ;Cell Cycle. 2015 Jan 21
• RB restricts DNA damage-initiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control.
  Bourgo, R. J., Thangavel, C., Ertel, A., Bergseid, J., McClendon, A. K., Wilkens, L., Witkiewicz, A. K., Wang, J. Y., Knudsen, E. S.> ;Mol Cell. 2011 Aug 19
• RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage.
  McClendon, A. K., Dean, J. L., Ertel, A., Fu, Z., Rivadeneira, D. B., Reed, C. A., Bourgo, R. J., Witkiewicz, A., Addya, S., Mayhew, C. N., Grimes, H. L., Fortina, P.,...> ;Gastroenterology. 2011 Oct
• Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.
  Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., Knudsen, E. S.> ;Oncogene. 2010 Jul 15
• Differential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell model.
  McClendon, A. K., Dean, J. L., Ertel, A., Knudsen, E. S.> ;PLoS One. 2010
• Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control.
  Reed, C. A., Mayhew, C. N., McClendon, A. K., Knudsen, E. S.> ;J Biol Chem. 2010 Jan 08
• RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1.
  Reed, C. A., Mayhew, C. N., McClendon, A. K., Yang, X., Witkiewicz, A., Knudsen, E. S.> ;Oncogene. 2009 Dec 17
• Modeling the effect of the RB tumor suppressor on disease progression: dependence on oncogene network and cellular context.
  Dean, J. L., McClendon, A. K., Stengel, K. R., Knudsen, E. S.> ;Oncogene. 2010 Jan 07
• Bimodal recognition of DNA geometry by human topoisomerase II alpha: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain.
  McClendon, A. K., Gentry, A. C., Dickey, J. S., Brinch, M., Bendsen, S., Andersen, A. H., Osheroff, N.> ;Biochemistry. 2008 Dec 16
• Cyclin-dependent kinase 4/6 activity is a critical determinant of pre-replication complex assembly.
  Braden, W. A., McClendon, A. K., Knudsen, E. S.> ;Oncogene. 2008 Nov 27
• Tryptophane-205 of human topoisomerase I is essential for camptothecin inhibition of negative but not positive supercoil removal.
  Frøhlich, R. F., Veigaard, C., Andersen, F. F., McClendon, A. K., Gentry, A. C., Andersen, A. H., Osheroff, N., Stevnsner, T., Knudsen, B. R.> ;Nucleic Acids Res. 2007
• DNA topoisomerase II, genotoxicity, and cancer.
  McClendon, A. K., Osheroff, N.> ;Mutat Res. 2007 Oct 1
• Ability of viral topoisomerase II to discern the handedness of supercoiled DNA: bimodal recognition of DNA geometry by type II enzymes.
  McClendon, A. K., Dickey, J. S., Osheroff, N.> ;Biochemistry. 2006 Sep 26
• The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.
  McClendon, A. K., Osheroff, N.> ;Biochemistry. 2006 Mar 7
• Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks.
  McClendon, A. K., Rodriguez, A. C., Osheroff, N.> ;J Biol Chem. 2005 Nov 25
• Biological characterization of MLN944: a potent DNA binding agent.
  Sappal, D. S., McClendon, A. K., Fleming, J. A., Thoroddsen, V., Connolly, K., Reimer, C., Blackman, R. K., Bulawa, C. E., Osheroff, N., Charlton, P., Rudolph-Owen, L. A.> ;Mol Cancer Ther. 2004 Jan
• Join now to see all